Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals
Oculis NASDAQ: OCS said its two Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema did not meet their primary endpoints, and the company does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug candidate in that indication.
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.77 per share a year ago.
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.76 per share a year ago.
Oculis Holding AG (OCS) Upgraded to Buy: Here's What You Should Know
Oculis Holding AG (OCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.55 per share a year ago.
Oculis Holding AG (OCS) Soars 6.3%: Is Further Upside Left in the Stock?
Oculis Holding AG (OCS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.56 per share a year ago.
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.44 per share a year ago.
Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline
Oculis Holding AG (OCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.38 per share a year ago.
Here's Why Momentum in Oculis Holding AG (OCS) Should Keep going
Oculis Holding AG (OCS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care
Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01. OCS-05 and OCS-02 also target interesting TAMs in neuro-ophthalmology and DMD. OCS's cash runway should last until late 2026, but if they don't generate an FDA-approved product soon, it could become an issue for shareholders.
